AR088372A1 - Solucion para administracion oral - Google Patents

Solucion para administracion oral

Info

Publication number
AR088372A1
AR088372A1 ARP120103877A ARP120103877A AR088372A1 AR 088372 A1 AR088372 A1 AR 088372A1 AR P120103877 A ARP120103877 A AR P120103877A AR P120103877 A ARP120103877 A AR P120103877A AR 088372 A1 AR088372 A1 AR 088372A1
Authority
AR
Argentina
Prior art keywords
acid
oral administration
solution
compound
quinolin
Prior art date
Application number
ARP120103877A
Other languages
English (en)
Inventor
Kondo Ayako
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR088372A1 publication Critical patent/AR088372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proporciona una solución adecuada para la administración oral de 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2-ona (compuesto (I)) o una sal del mismo. Y al menos un compuesto seleccionado del grupo que consiste en ácido láctico, ácido fosfórico, ácido glicólico, ácido málico, ácido tartárico, ácido cítrico, ácido succínico y ácido acético y que tiene un pH de 2,5 - 4,5.
ARP120103877A 2011-10-19 2012-10-18 Solucion para administracion oral AR088372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19

Publications (1)

Publication Number Publication Date
AR088372A1 true AR088372A1 (es) 2014-05-28

Family

ID=47178263

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103877A AR088372A1 (es) 2011-10-19 2012-10-18 Solucion para administracion oral

Country Status (35)

Country Link
US (7) US20140303183A1 (es)
EP (1) EP2768508B1 (es)
JP (1) JP6077534B2 (es)
KR (1) KR101856283B1 (es)
CN (2) CN107823131A (es)
AR (1) AR088372A1 (es)
AU (2) AU2012326978B2 (es)
BR (1) BR112014009330A2 (es)
CA (1) CA2851999C (es)
CL (1) CL2014000967A1 (es)
CO (1) CO6950486A2 (es)
CY (1) CY1117794T1 (es)
DK (1) DK2768508T3 (es)
EA (2) EA202190445A2 (es)
ES (1) ES2583137T3 (es)
HK (1) HK1196773A1 (es)
HR (1) HRP20160989T1 (es)
HU (1) HUE028869T2 (es)
IL (1) IL231988A (es)
IN (1) IN2014DN02987A (es)
JO (1) JO3190B1 (es)
LT (1) LT2768508T (es)
ME (1) ME02459B (es)
MX (1) MX347309B (es)
MY (1) MY169096A (es)
PL (1) PL2768508T3 (es)
PT (1) PT2768508T (es)
RS (1) RS54967B1 (es)
SG (1) SG11201401273SA (es)
SI (1) SI2768508T1 (es)
SM (1) SMT201600341B (es)
TW (2) TWI632921B (es)
UA (1) UA111506C2 (es)
WO (1) WO2013058411A1 (es)
ZA (1) ZA201402669B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
WO2017095266A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения (варианты)
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
US11013702B2 (en) * 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
JPWO2021029020A1 (es) * 2019-08-13 2021-02-18
CA3184425A1 (en) * 2020-06-30 2022-01-06 Mark C. Faulkner Compositions for controlling odor and itch and methods of and devices for administering same
WO2022218356A1 (zh) * 2021-04-13 2022-10-20 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP4584706B2 (ja) * 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4866349B2 (ja) * 2005-06-13 2012-02-01 大日本住友製薬株式会社 可溶化型製剤
CA2617920C (en) * 2005-09-01 2014-05-27 Baxter International Inc. Argatroban formulation comprising an acid as solubilizer
WO2008016165A2 (en) * 2006-07-31 2008-02-07 Asubio Pharma Co., Ltd. Liquid preparation
NZ584037A (en) * 2007-09-17 2012-08-31 Schering Corp Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
RU2537237C2 (ru) * 2007-09-21 2014-12-27 Астразенека Аб Растворимые дозированные формы, содержащие производные цефема, приемлемые для парентерального введения
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
US9511022B2 (en) * 2010-08-24 2016-12-06 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Also Published As

Publication number Publication date
CL2014000967A1 (es) 2014-10-03
US20200171023A1 (en) 2020-06-04
CN107823131A (zh) 2018-03-23
EA201490812A1 (ru) 2014-09-30
JP2014530801A (ja) 2014-11-20
IL231988A (en) 2017-09-28
KR101856283B1 (ko) 2018-05-09
IL231988A0 (en) 2014-05-28
HK1196773A1 (zh) 2014-12-24
RS54967B1 (sr) 2016-11-30
ME02459B (me) 2017-02-20
WO2013058411A1 (en) 2013-04-25
IN2014DN02987A (es) 2015-05-08
TW201737916A (zh) 2017-11-01
US20140303183A1 (en) 2014-10-09
CY1117794T1 (el) 2017-05-17
AU2017213570A1 (en) 2017-08-31
AU2012326978A1 (en) 2014-05-22
CA2851999A1 (en) 2013-04-25
AU2012326978B2 (en) 2017-08-31
NZ623523A (en) 2015-12-24
LT2768508T (lt) 2016-09-12
TWI679977B (zh) 2019-12-21
MY169096A (en) 2019-02-18
US20180271858A1 (en) 2018-09-27
CO6950486A2 (es) 2014-05-20
ES2583137T3 (es) 2016-09-19
TWI632921B (zh) 2018-08-21
JP6077534B2 (ja) 2017-02-08
CA2851999C (en) 2020-01-07
EP2768508A1 (en) 2014-08-27
MX2014004529A (es) 2014-08-01
PL2768508T3 (pl) 2016-12-30
EP2768508B1 (en) 2016-07-06
DK2768508T3 (en) 2016-08-29
HRP20160989T1 (hr) 2016-10-07
BR112014009330A2 (pt) 2017-04-11
JO3190B1 (ar) 2018-03-08
SMT201600341B (it) 2016-11-10
HUE028869T2 (en) 2017-01-30
US20240009186A1 (en) 2024-01-11
MX347309B (es) 2017-04-21
US20170182036A1 (en) 2017-06-29
PT2768508T (pt) 2016-08-17
EA202190445A2 (ru) 2021-08-31
US20160213665A1 (en) 2016-07-28
KR20140083032A (ko) 2014-07-03
UA111506C2 (uk) 2016-05-10
CN103889426A (zh) 2014-06-25
US20210236483A1 (en) 2021-08-05
SG11201401273SA (en) 2014-05-29
SI2768508T1 (sl) 2016-09-30
TW201330873A (zh) 2013-08-01
ZA201402669B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
AR088372A1 (es) Solucion para administracion oral
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
EA201390347A1 (ru) Лечение заболеваний
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
AR083100A1 (es) Monohidrato de derivados de aza-adamantano
BR112015029504A2 (pt) inibidores quinase
EA201690183A1 (ru) Замещенные пиразолопиридинамины
PH12014501425A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
UA106336U (uk) Сполука n-феніл-3-(уридин-2'-тіо-4'-гідроксі-6'-аміно)-сукцинімід, яка має потенційну фізіологічну властивість
TH152447A (th) องค์ประกอบทางเภสัชกรรม
TH154733A (th) อนุพันธ์เตตระไฮโดร-ไพริโด-ไพริมิดีน (tetrahydro-pyrido-pyrimidine)
TH128481A (th) 11-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี)-14,19-ไดออกซา-5,7,26-ไตรอะซา-เตตราไซโคล [19.3.1.1(2,6).1(8,12)]เฮปทาโคซา-1(25),2(26),3,5,8,10,12(27),16,21,23-เดคาอีน ซิเตรท ซอลท์

Legal Events

Date Code Title Description
FC Refusal